X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2%
Thu, 30 May

NOVARTIS has announced its results for the quarter ended March 2019. Here is a detailed performance review of the same:

NOVARTIS Quarterly Financials

No. of Mths
Qtr. Ending
3
Mar-18*
3
Dec-18*
3
Mar-19*
QoQ ChangeYoY Change
Net SalesRs m1,2531,3561,104-18.6%-11.9%
Other incomeRs m1,09611513417.1%-87.7%
TurnoverRs m2,3491,4711,238-15.8%-47.3%
ExpensesRs m1,4721,221905-25.9%-38.5%
Gross profitRs m-21913519947.1%
DepreciationRs m6109-4.2%42.2%
InterestRs m5100-100.0%-100.0%
Profit before taxRs m81924032435.0%-60.5%
TaxRs m55511112915.6%-76.8%
Profit after taxRs m26512919551.7%-26.2%
Gross profit margin%-17.510.018.0
Effective tax rate%67.746.439.7
Net profit margin%11.38.715.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter fell 11.9% on a year-on-year (YoY) basis. The expenses were down by 38.5% YoY during the same period.
  • The company's operating profit declined by 190.7% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 18.0% in 4QFY19 as against 17.5% in 4QFY18.
  • Depreciation charges increased by 42.2% and finance costs declined by 100.0% YoY, respectively.
  • Other income declined by 87.7% YoY during the quarter.
  • Net profit for the quarter declined by 26.2% YoY. Net profit margins during the quarter increased from 11.3% in 4QFY18 to 15.8% in 4QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 18.6% on a quarter-on-quarter (QoQ) basis. The expenses were down by 25.9% QoQ during the same period.
  • The company's operating profit increased by 47.1% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 18.0% in 4QFY19 as against 10.0% in 3QFY18.
  • Net profit for the quarter increased by 51.7% QoQ, while net profit margins increased from 8.8% in 3QFY18 to 15.8% in 4QFY19.

To see how NOVARTIS has performed over the last eight quarters, please visit here.

NOVARTIS Share Price Performance

Over the last one year, NOVARTIS share price has moved up from Rs 664.2 to Rs 702.3, registering a Gain of Rs 38.2 or around 5.7%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,339.1 (up 0.2%). Over the last one year it has moved up from 13,111.9 to 13,339.1, a gain of 227 points (up 1.7%).

Overall, the S&P BSE SENSEX is up 13.6% over the year.

Current Valuations

At the current price of Rs 702.3, the price to earnings (P/E) ratio of NOVARTIS stands at 455.1 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 32.1 times.

Equitymaster requests your view! Post a comment on "NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2%". Click here!

  

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 18, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - ACTAVIS COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS